Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001072 · ClinicalTrials.gov registry record · Phase 1
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT00001072 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 140 participants.
The verdict
NCT00001072, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
To evaluate, in HIV-negative volunteers, the safety and immunogenicity of ALVAC-HIV MN120TMGNP (vCP300) followed by or combined with boosting using rgp120/HIV-1SF2. To compare ALVAC-HIV vCP300 with ALVAC-RG rabies glycoprotein (vCP65) as a control. To evaluate an accelerated immunization schedule at 0, 1, 3, and 6 months versus 0, 1, 6, and 9 months. The combination of a live recombinant primer followed by a subunit boost has the potential to induce not only cytotoxic T lymphocytes but also neutralizing antibody.
Interventions
- BIOLOGICAL rgp120/HIV-1 SF-2
- BIOLOGICAL ALVAC-RG Rabies Glycoprotein (vCP65)
- BIOLOGICAL ALVAC-HIV MN120TMGNP (vCP300)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Est. Completion | 1999-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001072
The ClinicalTrials.gov registry entry for NCT00001072 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rgp120/HIV-1 SF-2 is the first listed.
NCT00001072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001072 about?
NCT00001072 is a clinical study titled "A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers". To evaluate, in HIV-negative volunteers, the safety and immunogenicity of ALVAC-HIV MN120TMGNP (vCP300) followed by or combined with boosting using rgp120/HIV-1SF2. To compare ALVAC-HIV vCP300 with ALVAC-RG rabies glycoprotein (vCP65) as a control. To evaluate an accelerated immunization schedule at...
What is the current status of trial NCT00001072?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. Estimated completion is 1999-01.
What interventions are being tested in trial NCT00001072?
The interventions under investigation include: rgp120/HIV-1 SF-2 (BIOLOGICAL), ALVAC-RG Rabies Glycoprotein (vCP65) (BIOLOGICAL), ALVAC-HIV MN120TMGNP (vCP300) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001072?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.